sur HBM Healthcare Investments AG (ETR:CH001262)
Mirum Pharmaceuticals to Acquire Bluejay Therapeutics for USD 820 Million
HBM Healthcare Investments has announced that its portfolio company, Bluejay Therapeutics, will be acquired by Mirum Pharmaceuticals. The transaction, valued at up to USD 820 million, includes USD 250 million in cash and USD 370 million in Mirum stock. Additionally, there are potential tiered milestone payments of up to USD 200 million. This deal follows HBM’s USD 7 million investment in Bluejay's Series C round in May 2024.
Upon closing, HBM Healthcare is set to receive approximately USD 6 million in cash, along with Mirum shares valued at USD 7 million. Further potential earnings include up to USD 3.7 million upon reaching specific sales milestones. Bluejay focuses on therapies for viral and liver diseases and is developing brelovitug, an antibody targeting chronic hepatitis D and B.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de HBM Healthcare Investments AG